资料单张
SCHERIPROCT SUPPOSITORIES
SCHEDULING STATUS
S4
PROPRIETARY NAME
(and dosage form):
SCHERIPROCT SUPPOSITORIES
COMPOSITION
1 suppository contains
prednisolone
caproate (1,4-pregnadiene-3,20-dione-11beta-17alpha,21-triol-21-caproate) 1,3 mg
and
cinchocaine
hydrochloride as the hydrochloride of (2-butoxy-N-(2-diethylaminoethyl)cinchonamide) 1 mg.
PHARMACOLOGICAL CLASSIFICATION
A. 11.8 Suppositories.
PHARMACOLOGICAL ACTION
Prednisolone exerts an antiinflammatory and antipruritic effect. Capillary dilatation, intercellular oedema and tissue
infiltration regress; capillary proliferation is suppressed.
As a local anaesthetic, cinchocaine eases the pain.
INDICATIONS
Short term symptomatic relief of perianal discomfort, inflammation and itching caused by thrombosed haemorrhoids, anal
fissure and pruritus ani.
CONTRA-INDICATIONS
Hypersensitivity to any of the ingredients.
Viral infections, primary bacterial or fungal infections in the treatment area. Secondary infections of the skin in the
absence of appropriate antiinfective therapy. Known sensitivity to local anaesthetics.
Corticosteroids have been shown to be teratogenic in animals following dermal application. As these agents are absorbed
percutaneously, teratogenicity following topical application cannot be excluded. Therefore, Scheriproct should not be
used during pregnancy.
The excretion of effective amounts of glucocorticoid with the breast milk is improbable.
WARNINGS
This product should not be used continuously for more than 7 days. If symptoms do not disappear quickly, discontinue
treatment and consult your doctor. Certain anal disorders require specific treatment and a proctological examination. In
case of bleeding, consult a doctor promptly.
DOSAGE AND DIRECTIONS FOR USE
The anal region should be cleaned thoroughly before using Scheriproct, which is best applied
阅读完整的文件
资料单张 